{"name": "ACADIA Pharmaceuticals",
 "permalink": "acadia-pharmaceuticals",
 "crunchbase_url": "http://www.crunchbase.com/company/acadia-pharmaceuticals",
 "homepage_url": "http://www.acadia-pharm.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@acadia-pharm.com",
 "phone_number": "(858) 558-2871",
 "description": "",
 "created_at": "Wed Jan 12 04:19:20 UTC 2011",
 "updated_at": "Wed May 22 05:11:30 UTC 2013",
 "overview": "\u003Cp\u003EACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The Company maintains two wholly owned subsidiaries: ACADIA Pharmaceuticals AB based in Malmo, Sweden and ACADIA Pharmaceuticals A/S based in Denmark. The Company is developing a portfolio consisting of four product candidates, including the compound, pimavanserin, which it is developing for three separate neurological and psychiatric indications in collaboration with Biovail Laboratories International SRL (Biovail), a subsidiary of Biovail Corp. The indications are Parkinson\u00e2\u20ac\u2122s disease psychosis, which is in Phase III development, adjunctive therapy in schizophrenia, and Alzheimer\u00e2\u20ac\u2122s disease psychosis, for which it is initiating a Phase II feasibility study. \u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       46],
      "assets/images/resized/0011/6927/116927v1-max-150x150.png"],
     [[163,
       50],
      "assets/images/resized/0011/6927/116927v1-max-250x250.png"],
     [[163,
       50],
      "assets/images/resized/0011/6927/116927v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "President and CEO",
    "person":
     {"first_name": "Uli",
      "last_name": "Hacksell",
      "permalink": "uli-hacksell",
      "image": null}},
   {"is_past": false,
    "title": "Executive Vice President, CFO",
    "person":
     {"first_name": "Thomas",
      "last_name": "H. Aasen",
      "permalink": "thomas-h-aasen",
      "image": null}},
   {"is_past": false,
    "title": "Member, Board of Directors and Audit Committee",
    "person":
     {"first_name": "Laura",
      "last_name": "A. Brege",
      "permalink": "laura-a-brege",
      "image":
       {"available_sizes":
         [[[150,
            150],
           "assets/images/resized/0026/6349/266349v1-max-150x150.jpg"],
          [[200,
            200],
           "assets/images/resized/0026/6349/266349v1-max-250x250.jpg"],
          [[200,
            200],
           "assets/images/resized/0026/6349/266349v1-max-450x450.jpg"]],
        "attribution": ""}}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$15M",
 "funding_rounds":
  [{"round_code": "unattributed",
    "source_url": "https://www.fis.dowjones.com/article.aspx?ProductIDFromApplication=29\u0026aid=DJFVLS0020110111e71b0002v\u0026r=Rss\u0026s=DJFVLS",
    "source_description": "Public Acadia Pharma To Raise $15M From NEA, Venrock, Others ",
    "raised_amount": 15000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2011,
    "funded_month": 1,
    "funded_day": 11,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "New Enterprise Associates",
         "permalink": "new-enterprise-associates",
         "image":
          {"available_sizes":
            [[[150,
               110],
              "assets/images/resized/0001/5083/15083v3-max-150x150.png"],
             [[150,
               110],
              "assets/images/resized/0001/5083/15083v3-max-250x250.png"],
             [[150,
               110],
              "assets/images/resized/0001/5083/15083v3-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Venrock",
         "permalink": "venrock",
         "image":
          {"available_sizes":
            [[[150,
               52],
              "assets/images/resized/0001/6279/16279v1-max-150x150.jpg"],
             [[250,
               87],
              "assets/images/resized/0001/6279/16279v1-max-250x250.jpg"],
             [[351,
               123],
              "assets/images/resized/0001/6279/16279v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "3911 Sorrento Valley Blvd",
    "address2": "",
    "zip_code": "92121 ",
    "city": "San Diego",
    "state_code": "CA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "ACADIA Pharmaceuticals Announces $86 Million Equity Financing",
    "stoned_year": 2012,
    "stoned_month": 12,
    "stoned_day": 13,
    "source_url": "http://finance.yahoo.com/news/acadia-pharmaceuticals-announces-86-million-140000179.html",
    "source_text": "",
    "source_description": "ACADIA Pharmaceuticals Announces $86 Million Equity Financing",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "ACADIA Pharmaceuticals",
      "permalink": "acadia-pharmaceuticals"}}],
 "ipo":
  {"valuation_amount": null,
   "valuation_currency_code": "USD",
   "pub_year": 2013,
   "pub_month": 5,
   "pub_day": 21,
   "stock_symbol": "NASDAQ:ACAD"},
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}